It is an anti-ulcer peptide (9-12), interacting with NO-system (13), and, unlike other peptides, it is particularly stable in gastric juice (14) and is used consistently without a carrier (9-11, 13-24), being safe in patients with the inflammatory bowel disease (coded PL-10, PLD 116, PL 14736) (21)
Long half-life (characterized in studies): Reported as long-acting in preclinical and clinical research, supporting extended-interval dosing within those study protocols
The value depends on context: your baseline, your stress load, your nutrition consistency, and whether your lab patterns match the story your symptoms are telling
No human dosing data from controlled trials exists for either peptide individually or in combination
As with any therapeutic compound, application under physician guidance is recommended to ensure appropriate concentration and formulation
GHK-Cu may support the bodys response to these treatments by providing the raw materials and signaling pathways needed for effective tissue rebuilding